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Abstract
Background: The transient receptor potential ankyrin 1 (TRPA1) channel, localized to airway sensory nerves, has been
proposed to mediate airway inflammation evoked by allergen and cigarette smoke (CS) in rodents, via a neurogenic
mechanism. However the limited clinical evidence for the role of neurogenic inflammation in asthma or chronic obstructive
pulmonary disease raises an alternative possibility that airway inflammation is promoted by non-neuronal TRPA1.
Methodology/Principal Findings: By using Real-Time PCR and calcium imaging, we found that cultured human airway cells,
including fibroblasts, epithelial and smooth muscle cells express functional TRPA1 channels. By using immunohistochem-
istry, TRPA1 staining was observed in airway epithelial and smooth muscle cells in sections taken from human airways and
lung, and from airways and lung of wild-type, but not TRPA1-deficient mice. In cultured human airway epithelial and
smooth muscle cells and fibroblasts, acrolein and CS extract evoked IL-8 release, a response selectively reduced by TRPA1
antagonists. Capsaicin, agonist of the transient receptor potential vanilloid 1 (TRPV1), a channel co-expressed with TRPA1 by
airway sensory nerves, and acrolein or CS (TRPA1 agonists), or the neuropeptide substance P (SP), which is released from
sensory nerve terminals by capsaicin, acrolein or CS), produced neurogenic inflammation in mouse airways. However, only
acrolein and CS, but not capsaicin or SP, released the keratinocyte chemoattractant (CXCL-1/KC, IL-8 analogue) in
bronchoalveolar lavage (BAL) fluid of wild-type mice. This effect of TRPA1 agonists was attenuated by TRPA1 antagonism or
in TRPA1-deficient mice, but not by pharmacological ablation of sensory nerves.
Conclusions: Our results demonstrate that, although either TRPV1 or TRPA1 activation causes airway neurogenic
inflammation, solely TRPA1 activation orchestrates an additional inflammatory response which is not neurogenic. This
finding suggests that non-neuronal TRPA1 in the airways is functional and potentially capable of contributing to
inflammatory airway diseases.
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Introduction
A subset of primary sensory neurons expresses and releases the
neuropeptides calcitonin gene-related peptide (CGRP) and
tachykinins, substance P (SP) and neurokinin A (NKA), producing
a series of inflammatory responses, collectively referred to as
neurogenic inflammation [1]. Airway neurogenic inflammation,
mainly mediated by SP and NKA, via the activation of NK1 and
NK2 receptors, encompasses a series of transient phenomena,
including plasma protein extravasation and neutrophil adhesion to
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the vascular endothelium, which have been implicated in the
mechanisms of airway inflammatory diseases, including asthma
and chronic obstructive pulmonary diseases (COPD) [1,2]. In
experimental animals, SP/NKA contribute to the early inflam-
matory response evoked by common aggravants of asthma and
COPD, such as allergens [3] and cigarette smoke [4]. However,
despite decades of intense research, there is little [5] or no
evidence that neuropeptide activation of NK1/NK2 receptors is
responsible for the typical features of asthma or COPD, including
cytokine release, chronic inflammatory cell infiltration, and airway
hyperresponsiveness.
Peptidergic sensory neurons express the transient receptor
potential vanilloid 1, (TRPV1) [6] and ankyrin 1 (TRPA1)
channels [7,8,9,10]. TRPV1 stimulants, such as capsaicin, low
extracellular pH, and certain lipid derivatives [6,11,12,13]), or
TRPA1 stimulants, such as several exogenous pollutants with toxic
liability and a host of endogenous by-products of oxidative and
nitrative stress [14,15,16,17,18,19], release sensory neuropeptides
and produce airway neurogenic inflammation [20,21]. Recently, it
has been shown that activation of TRPA1, but not TRPV1,
modulates airway inflammatory response in murine models of
allergic asthma, reactive airways dysfunction syndrome (RADS)
and COPD, induced by cigarette smoke [20], reactive acetamin-
ophen metabolite [21] or allergen [22]. Such observations have
advanced the hypothesis that airway sensory nerves via a
neurogenic inflammatory mechanism mediate these clinical
phenomena. However, as clinical trials in the last 20 years with
NK1/NK2 receptor antagonists have shown little efficacy in
asthma [23,24], and, with no reported therapeutic role so far
reported by the use of NK1/NK2 receptor antagonists in COPD,
it seems unlikely that SP/NKA released from sensory nerves are
the sole and the major contributors of TRPA1-mediated
inflammation in the airways.
The apparent contradiction that activation of both TRPV1 and
TRPA1 causes neurogenic airway inflammation, but only TRPA1
agonists produce hallmark features of airway inflammation in
models of asthma and COPD [20,22,25], could be explained if
TRPA1 channels were expressed not only by sensory nerves, but
also by non-neuronal cells of the airways, from which they
orchestrate neurogenic-independent inflammatory responses. Re-
cent identification of functional TRPA1 channel in enterochro-
maffin cells of the gastrointestinal tract [26] vascular endothelial
cells [27], and keratinocytes [28] support the proposal that
TRPA1 agonists may act on channels expressed by non-neuronal
cells to promote key inflammatory responses. Here we present
evidence that non-neuronal cells in human and murine airways
express TRPA1, where it promotes a non-neurogenic inflamma-
tory response, which may contribute to asthma and COPD.
Results
TRPA1 expression in non-neuronal cells of the human
and mouse respiratory tract
To assess the expression of TRPA1 in different types of human
airway/pulmonary cells, (either immortalized cell lines or primary
cultures), we performed Real-Time PCR on total mRNA isolated
from human alveolar type II epithelium-like adherent cell line
(A549), human small airway epithelial cells (SAEC), human
embryonic lung fibroblasts (IMR90), normal human lung fibro-
blasts (NHLF), and human bronchial smooth muscle cells
(HBSMC). Using specific TaqMan primers and probe sets, we
found detectable levels of human TRPA1 transcript in all the
examined cells (Figure 1A). To investigate the expression of
TRPA1 protein in non-neuronal cells of human airways and lung
we performed an immunohistochemical evaluation with a specific
human TRPA1 antibody [29]. Replacing the primary antibody
with normal serum abolished the intense staining, present in
epithelial and smooth muscle cells (Figure 1B). TRPA1 staining
was also identified in non-neuronal cells of airway/lung tissue
taken from wild-type (Trpa1+/+), but not in TRPA1-deficient
(Trpa12/2) mice (Figure 1C), by using a TRPA1 antibody that
recognizes the middle region of the protein. In particular, intense
staining was detected in the bronchial epithelium and smooth
muscle layer. Staining was completely absent when the TRPA1
antibody was pre-adsorbed with the immunizing peptide
(Figure 1C), confirming specificity. Absence of staining in
trigeminal ganglion (an area enriched with TRPA1 expressing
neurons) from Trpa12/2 mice, compared with the marked protein
expression in ganglia taken from Trpa1+/+ mice (Figure S1A),
conclusively supports the specificity of the antiserum, and,
accordingly, the immunohistochemical findings obtained in the
airway. In slices of human and mouse airway/lung, antibodies for
specific markers for epithelial cells (cytokeratin) or a-smooth
muscle cells (a-smooth muscle actin) stained, as predicted,
bronchial/lung epithelial and smooth muscle layers, respectively.
A similar pattern of staining was found in both human and mouse
serial sections with the antibodies for the human or mouse
TRPA1, respectively (Figure 1B and C). By using immunofluo-
rescence, staining for cytokeratin and TRPA1 merged in a large
proportion of epithelial cells and staining for a-smooth muscle
actin and TRPA1 merged in smooth muscle cells both in human
and mouse lung tissues (Figure S1B and C). In additional
experiments, using a TRPV1 antiserum which recognizes both
human and mouse protein [30], we found that TRPV1 staining
was absent in epithelial and smooth muscle cell layers in both
human and mouse airways (Figure S2A and B). Mouse trigeminal
ganglia have been used as control (Figure S2C).
Airway/lung cells express a functional TRPA1 channel
TRP channels are generally non-selective cation channels, and
TRPA1 stimulation results in a massive influx of calcium into the
stimulated cells [9]. Thus, to verify if mRNA and the resulting
protein expressed by the different types of human airway cells
produces and represents a functional channel, respectively, we
exposed fibroblasts (IMR90 and NHLF), epithelial (A549 and
SAEC), and smooth muscle (HBSMC) cells to TRPA1 agonists,
including cinnamaldehyde [31], acrolein [14], and cigarette smoke
aqueous extract (CSE). CSE contains more than 4,000 chemical
compounds [32], and some of them have been previously
identified as TRPA1 activators [20,33,34]. Administration of all
the three TRPA1 agonists produced concentration-dependent
elevation in intracellular calcium of slightly different intensity in all
tested cells (Table 1). It should be underlined that the intensity of
the response to TRPA1 agonists may be affected by changes in
expression occurring in cell lines or even cultured cells. Thus, if the
qualitative significance of the results is obvious, their quantitative
value as predictor of the in vivo response to TRPA1 agonists
remains to be determined. The TRPA1 selective antagonists, HC-
030031 [35] or AP18 [36], invariably prevented the effects of
submaximal agonist concentrations (Figure 2A–C and Figure
S3A–C). HC-030031 or AP18 did not affect the response to the
activating peptide of the PAR-2 receptor, thus indicating
selectivity of the pharmacological intervention. The observation
that calcium response to CSE was completely abated by TRPA1
antagonists indicates that calcium response caused by CSE is
entirely mediated by TRPA1 stimulation. The selective and potent
TRPV1 agonist, capsaicin (1 mM), failed to produce any visible
TRPA1 Promotes Airway Non-Neurogenic Inflammation
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calcium response in SAEC, A549, NHLF, IMR90, and HBSMC
cells (data not shown).
In vivo exposure to acrolein or cigarette smoke (CS)
induces KC release via a non-neuronal mechanism
Next we asked whether TRPA1 could contribute to the release
of inflammatory mediators in bronchoalveolar lavage (BAL) fluid
following exposure to CS in mice. BAL taken from wild-type mice
(C57BL/6 background [14]) and exposed to CS showed increased
levels of a series of mediators, including interleukin-1b (IL-1b),
neutrophil chemoattractant chemokine (KC), monocyte chemo-
tactic protein-1 (MCP-1), tissue inhibitor of metalloproteinases-1
(TIMP-1), metalloproteinases-9 (MMP-9), and interleukin (IL) -2, -
5, -13. Increases in KC, IL-5, MMP-9, and TIMP-1 by CS were
significantly reduced in Trpa12/2 mouse BAL, indicating a role of
TRPA1 in these responses (Figure S4). Information about methods
is available online as (Text S1). IL-6, macrophage inflammatory
protein-1a (MIP-1a), IL-4, IL-10, and neuropeptides, SP and
NKA levels were either below the limits of detection for the assay
or were not increased (data not shown).
CS inhalation has been shown to increase plasma protein
extravasation (PPE) in guinea-pig trachea via a neurogenic
mechanism [4] and TRPA1 receptor activation [20]. In the
present study, we confirmed that instillation of acrolein and CSE,
as well as capsaicin or SP, into the C57BL/6 mouse tracheal
lumen increased PPE, an effect that was prevented by pretreat-
ment with a SP receptor (NK1) antagonist (Figure 3A–C). The
effect of acrolein or CSE was selectively abated by HC-030031
Figure 1. TRPA1 channel expression in non-neuronal cells of the human and mouse respiratory tract. (A) Total RNAs were extracted
from primary small airways epithelial cells (SAEC), human type II alveolar epithelial cells (A549), human primary smooth muscle cells (HBSMC), human
embryonic lung fibroblasts (IMR90) and primary normal human lung fibroblasts (NHLF) and relative TRPA1 mRNA amounts were measured by
Taqman Real-Time PCR assay. Results are normalized to the reference gene, b-actin. Each column represents mean 6 SEM of n.2 independent
experiments. Immunohistochemical analysis of TRPA1 expression in samples taken from human (B) or Trpa1+/+ and Trpa12/2mouse airways and lung
(C). Representative images of TRPA1 immunostaining show intense staining in epithelial and smooth muscle cells in human tissue. No staining is
detected in human samples incubated with the normal serum peptide (Negative control). (C) Incubation with TRPA1 antibody shows a strong
staining in epithelial and smooth muscle cells in tissues taken from Trpa1+/+ mice, but not in those from Trpa12/2 mice. Preadsorption of the TRPA1
antibody with the peptide used for immunization abolished staining (Peptide). Staining for cytokeratin and a-smooth muscle actin (a-SMA) overlaps
with the TRPA1 staining in the bronchial epithelium and smooth muscle layer in serial section of human and mice airways/lung tissues (B and C).
Scale bar 100 mm.
doi:10.1371/journal.pone.0042454.g001
Table 1. Potency (EC50 and CI) of the various TRPA1 agonists in different non-neuronal cell types of the human respiratory tract.
Cinnamaldehyde EC50 (CI) mM Acrolein EC50 (CI) mM Cigarette Smoke Extract EC50 (CI) OD
A549 10.9 (6.4–18.6) 7.3 (4.7–11.4) 0.006 (0.001–0.05)
SAEC 46.3 (25.9–82.9) 56.9 (35.1–92.4) 0.026 (0.01–0.05)
IMR90 2.7 (1.3–5.3) 2.9 (1.2–7.6) 0.05 (0.02–0.07)
NHLF 6.6 (4.9–8.8) 4.4 (3.4–5.7) 0.01 (0.001–0.02)
HBSMC 6.7 (5.57–8.1) 6.3 (4.0–10.0) 0.008 (0.006–0.010)
doi:10.1371/journal.pone.0042454.t001
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and that of capsaicin by the TRPV1 selective antagonist,
capsazepine [37] and all responses (including that of SP
instillation) by the NK1 receptor antagonist, L-733,060
(Figure 3A–C). Thus, either TRPV1 or TRPA1 stimulants were
able to cause neurogenic inflammation in mouse airways, an effect
mediated by NK1 receptors.
To investigate whether non-neuronal TRPA1 was involved in
the mechanism responsible for inflammatory mediator release by
CS, we studied KC release under different circumstances. First, we
confirmed using a different colony of Trpa1+/+ and Trpa12/2 mice
(B6129P) and a slightly different protocol (which optimized KC
release in BAL) that CS releases KC in BAL from Trpa1+/+ mice,
and that this effect was significantly reduced in Trpa12/2 mice
(Figure 3D). Next, we gave capsaicin, SP, acrolein, or CSE to
C57BL/6 mice via intratracheal instillation, and BAL were
collected 24 hours later for KC determination. CSE or acrolein,
but not capsaicin or SP, significantly increased KC in BAL
(Figure 3E and F), indicating that the effect of CSE or acrolein is
not mediated by sensory neuron activation. In addition, pretreat-
ment with HC-030031 significantly reduced KC release, indicat-
ing TRPA1 involvement in this phenomenon (Figure 3E and F).
Acrolein-induced KC release was completely absent in Trpa12/2
mice (C57BL/6) (Figure 3G). Noteworthy, in order to exclude the
involvement of a neurogenic mechanism in KC release, C57BL/6
mice were pretreated with NK1 receptor antagonist, L-733,060,
prior to acrolein or CSE exposure. Indeed, it is known that, upon
TRPA1/TRPV1 activation, neuropeptides released from periph-
eral terminals of primary neurons, including SP, NKA, and
CGRP, exert their action through NK1 and NK2 receptors. Here
we demonstrated that the pretreatment with NK1 receptor
antagonist failed to reduce the increase of KC evoked by either
acrolein or CSE (Figure 3E and F), thus excluding a major
involvement of neurogenic contribution in the inflammatory
response leading to KC accumulation.
Further demonstration of the role of extra-neuronal TRPA1 in
KC release was obtained by using resiniferatoxin (RTX), a
selective and potent TRPV1 activator [38] which defunctiona-
lizes/destroys TRPV1 expressing afferents, and consequently
TRPA1 expressing neurons and neuronal responses to TRPA1
agonists [39,40]. In C57BL/6 mice treated with a high,
desensitizing dose of RTX (50 mg/Kg), acrolein-induced PPE
was completely abolished (Figure 3H). In contrast, acrolein-
induced increase in KC in BAL fluid (a response mediated by
TRPA1 because it is absent in TRPA1-deficient mice) remained
unchanged after RTX treatment (Figure 3I).
Acrolein and CSE exposure releases IL-8 via TRPA1
stimulation
Finally, we explored whether what we found in vivo in mice
could have a counterpart in vitro in human cells. For this purpose
we studied whether TRPA1 stimulation could release IL-8 (the
human analogue of KC) from human non-neuronal cells of the
respiratory tract. We previously demonstrated that acrolein and
CSE elicited IL-8 release from either immuno-competent cells,
including alveolar macrophages [41], and structural cells, includ-
ing lung fibroblasts, airway epithelial cells [25] and airway smooth
muscle cells [42]. Here, in SAEC, NHLF and HBSMC, we
observed that overnight exposure to acrolein evoked a concentra-
tion-dependent IL-8 release (Figure 4), a response that was
significantly reduced by HC-030031 and AP-18 (Figure 4),
suggesting the involvement of the TRPA1 channel in this pathway.
Similar results were obtained by using CSE as a stimulus (Figure 5).
Overnight exposure to CSE up to 0.1 optical density (OD) did not
affect cell viability (Figure S5A–C). CSE induced a concentration
Figure 2. Functional TRPA1 is expressed in human airway/lung
cells. Intracellular calcium response was used to assess agonist-induced
TRPA1 activation in small airways epithelial cells (SAEC) (A), normal
human lung fibroblasts (NHLF) (B) and bronchial smooth muscle cells
(HBSMC) (C). Typical traces and pooled data of the concentration-
dependent calcium response evoked by the selective TRPA1 agonists,
cinnamaldehyde (CNM, typical traces and black circles) and acrolein
(ACR, grey circles), in all different cell types in primary culture. Similarly
to CNM and ACR, cigarette smoke extract (CSE, black triangles)
produces in all the different types of cells a concentration-dependent
calcium response. Responses to CNM, ACR and CSE are prevented by
selective TRPA1 antagonists, HC-030031 (HC, 10 mM) and AP18 (10 mM).
The activating peptide (SLIGKV-NH2) of the PAR-2 receptor (PAR-2 AP,
100 mM) elicits a calcium response that is not modified by TRPA1
antagonists. Veh is a combination of vehicles of HC and AP18. Values
represent mean 6 SEM of n.25 cells. *P,0.05 vs. Veh.
doi:10.1371/journal.pone.0042454.g002
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(0.01–0.07 OD)- dependent release of IL-8 from SAEC, NHLF
and HBSMC, a response that was significantly reduced by
pretreatment with TRPA1 antagonists (Figure 5). It should be
noted that the action of acrolein and CSE was particularly
pronounced in HBSMC, where it was significantly, but not
completely, blocked by TRPA1 antagonism (Figure 4C and 5C).
The observation that TRPA1 antagonists did not affect IL-8
release evoked by IL-1b or tumor necrosis factor-a (TNF-a),
indicated selectivity of the antagonists (Figure S5D–I).
Discussion
By using functional cellular assays coupled with Real-Time
PCR, we demonstrate that TRPA1 is expressed and functional in
different human pulmonary non-neuronal cells. In particular,
TRPA1 mRNA was detected at various levels of expression in
human lung fibroblasts, small airways epithelial cells and smooth
muscle cells. In parallel, we performed immunohistochemical and
immunofluorescence studies demonstrating the expression of
TRPA1 in non-neuronal cells both in mice and human pulmonary
tissues. The intense staining found in epithelial and smooth muscle
cells in tissues obtained from wild-type mice, and the absence of
staining in tissues from TRPA1-deficient mice, strongly supports
the proposal that TRPA1 expression localizes to non-neuronal
pulmonary cells. The marked staining in trigeminal ganglia (TG;
an area enriched with TRPA1 expressing sensory neurons) taken
from wild-type mice, compared with the absence of staining in TG
taken from TRPA1-deficient mice, conclusively supports the
specificity of the antiserum, and strengthens the findings obtained
in the mouse respiratory system. The identification of TRPA1
positive staining in human airway tissue which was virtually
identical to that found in mice supports a similar extra-neuronal
localization of TRPA1 in man.
TRP channels are non-selective cation channels, and their
activation usually results in increase in intracellular calcium [9].
The present observation that TRPA1 agonists, cinnamaldehyde,
acrolein, and CSE [7,14,20], produced calcium responses in
airway fibroblasts, epithelial and smooth muscle cells, and selective
channel antagonists abated these responses, demonstrated that the
TRPA1 channel in these cells is functional. In contrast, the failure
of the potent TRPV1 agonist, capsaicin, to elicit any calcium
response in any cell type rules out the possibility that cultured cells
express functional TRPV1 channels. These functional data are
corroborated by failure to detect any TRPV1 staining in human or
mouse airway epithelial or smooth muscle cells. The neutrophil
chemoattractant, IL-8, may be released from epithelial cell lines
following TRPV1 or TRPA1 activation [29,43], and primary
airway fibroblasts and epithelial cells release IL-8 after exposure to
acrolein or CSE in vitro [25]. Here, we demonstrated that TRPA1
activation in fibroblasts, and epithelial and smooth muscle cells,
resulted in the release of IL-8. Present data show that all three
TRPA1 activators, cinnamaldehyde, acrolein, and CSE, release
IL-8, and TRPA1 antagonists selectively attenuate the response.
While cinnamaldehyde has primarily a pharmacological signifi-
cance, acrolein is one of the major a,b-unsaturated aldehydes
present in CS, and CSE contains additional molecules, recently
identified as TRPA1 agonists, such as crotonaldehyde [20],
acetaldehyde [33], and nicotine [9]. All these compounds may
target TRPA1 in sensory nerve terminals to produce an early,
neurogenic component of the inflammatory response to CS [20].
However, present findings show that all these agents target
TRPA1 also in non-neuronal airway and lung cells to release IL-8.
CS inhalation in rodents results in an early TRPA1-dependent
[20] inflammatory response, which in tracheobronchial tissue is
mainly represented by PPE [4], a phenomenon entirely mediated
by a neurogenic, SP/NKA- and NK1-dependent mechanism
[4,44]. TRPV1 and TRPA1 are co-expressed in a subset of
neuropeptide containing primary sensory neurons [10], and their
activation is known to promote neurogenic inflammation. Here,
we confirm this principle by using the TRPV1 agonist, capsaicin,
and TRPA1 agonists, acrolein and CS, which all produced an
NK1 receptor-dependent increase in PPE. As expected, intratra-
cheal application of SP, which is released from sensory nerve
terminals by both TRPV1 and TRPA1 agonists, increased PPE,
via NK1 receptor activation. However, when we studied the
ability of capsaicin and SP to release KC, the murine analogue of
IL-8, a clear dissociation between TRPV1 and the TRPA1
agonists was observed. The two TRPA1 activators, acrolein and
CS, were both able to cause a delayed (observed 24 hours after
the administration of the stimulus) and robust response. In
contrast, capsaicin and SP failed to increase KC in mouse BAL.
Thus, in the mouse, in vivo TRPA1 agonists increase KC in BAL,
whereas capsaicin or SP (the final mediator of neurogenic
inflammation) does not. The observation that sensory nerve
ablation by RTX [39,40], while it abolished the neurogenic
increase in PPE, failed to affect the KC increase in BAL
produced by acrolein, indicates that TRPA1-dependent KC
increase does not involve neurogenic mechanisms, and strongly
supports the view that TRPV1 and TRPA1 agonists act at
different cell types. Capsaicin stimulates TRPV1, whose expres-
sion in the airways is selectively confined to sensory nerve
terminals, to promote, via SP/NKA, neurogenic inflammation.
Acrolein and CS, via TRPA1, may activate this same neurogenic
pathway. However, acrolein and CS also act on non-neuronal
TRPA1-expressing cells to promote additional inflammatory
responses, such as IL-8/KC release.
These data and conclusions, obtained from in vitro experiments
in human cells and in vivo studies in C57BL/6 mice, were
corroborated by genetic studies in TRPA1-deficient mice. The KC
release by acrolein was, in fact, abated, and that by CS was
markedly reduced in TRPA1-deficient mice. The main aggravant
factor in COPD is the irritant effect of CS. A large series of CS
constituents have been shown to activate TRPA1 [9,20,33], and
oxidative stress and its by-products, including 4-hydroxy-2-none-
nal, have been proposed to contribute to the mechanism of COPD
[45]. Present data suggest that, in rodents, CS exposure first
activates an early neurogenic inflammatory response, which is
entirely mediated by TRPA1 [4,20]. However, a second and
delayed action of CS, in part mediated by TRPA1, encompasses
the release of IL-8/KC. If neurogenic inflammation is not relevant
in human airway disease, it is possible that TRPA1 plays a role in
COPD because stimulants contained in CS may promote
inflammatory mediator release through channel activation in
non-neuronal cells. The observation that, in addition to cell lines
[29], human epithelial cells in primary culture (fibroblasts,
epithelial and smooth muscle cells) express a functional channel
and release IL-8 via TRPA1 activation suggests that the biological
response mediated by non-neuronal TRPA1 observed in vivo in
mice may be present in humans.
TRPA1 has been proposed as a sensor of byproducts of
oxidative and nitrative stress [46], and oxidative stress and its by-
products, including 4-hydroxy-2-nonenal, have been suggested to
contribute to the mechanism of asthma [47]. Accidental exposure
to a number of environmental irritants, many of which are now
identified as TRPA1 stimulants [14,48,49,50,51], has been
reported to cause asthma-like symptoms, a condition that has
been defined as RADS [52,53,54]. The association between
acetaminophen use and the increased prevalence of asthma in
TRPA1 Promotes Airway Non-Neurogenic Inflammation
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children [55] has been attributed to the ability of the reactive drug
metabolite, N-acetyl-p-benzoquinone imine, to activate TRPA1 in
the airways [21]. Present data, proposing that non-neuronal
TRPA1, rather than the channel expressed in sensory nerve
terminals, contributes to the mechanism of inflammatory airway
diseases, offer a novel interpretation for the recent and important
finding that ovalbumin-sensitized TRPA1-deficient mice, but not
TRPV1-deficent mice, exhibit a much reduced inflammatory
Figure 3. In vivo KC release via a non-neuronal TRPA1-dependent mechanism. (A) Intratracheal instillation (i.t., 30 ml) of substance P (SP,
25 nM), capsaicin (CPS, 100 mM) in C57BL/6 mice increases Evans blue dye extravasation (PPE) in trachea and bronchi an effect prevented by L-
733,060 (NK1 receptor antagonist, NK1-A; 2 mmol/kg, i.v.) and capsazepine (CPZ; 30 mg/kg, i.p.) but not by HC-030031 (HC; 300 mg/kg, i.g.). (B) L-
733,060 and HC, but not CPZ prevent acrolein (ACR, 5 mM, i.t.)- and (C) cigarette smoke extract (CSE, 1 OD, i.t.)-evoked increase in PPE in C57BL/6
mouse trachea and bronchi. Each column represents mean 6 SEM of at least 5 mice. Veh is the vehicle of the various agonists. 1P,0.05 vs. Veh;
*P,0.05 vs. treated group. (D) Cigarette smoke (CS)-evoked increase in KC in BAL from Trpa1+/+ is reduced in Trpa12/2 mice. Each column represents
mean 6 SEM. 1P,0.05 vs. air-exposed Trpa1+/+ mice. #P,0.05 vs. Trpa1+/+ CS group. (E) ACR (5 mM, i.t.), but not CPS (100 mM, i.t.) or SP (25 nM, i.t.)
increases KC release in BAL. HC, but not L-733,060, reduces the increase in KC release by ACR (E) or CSE instillation (1 OD, i.t.) (F). (G) ACR (5 mM, i.t.)-
evoked increase in KC in BAL is practically absent in BAL of Trpa12/2 mice. Resiniferatoxin-desensitization (RTX-DES) abolished PPE-induced by ACR
(5 mM, i.t.) (H), while did not modify the ACR-evoked KC release (I). Veh-DES is the vehicle of RTX. Each column represents mean 6 SEM of at least 5
mice. 1P,0.05 vs. Veh or Veh-Trpa1+/+; *P,0.05 vs. treated group; #P,0.05 vs. ACR-Trpa1+/+.
doi:10.1371/journal.pone.0042454.g003
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phenotype after allergen exposure, with marked reduction in both
cytokine release and hyperresponsiveness [22]. If these data
demonstrate that TRPV1 is not involved, they suggest a major role
for TRPA1. Apart from a recent paper showing that nasally
administered SP slightly increases airway hyperresponsiveness in
mice [5], to the best of our knowledge, there is no evidence in past
or recent literature that pharmacological or genetic interventions
on sensory nerves, including sensory nerve desensitization by
capsaicin, pharmacological blockade or genetic deletion of NK1/
NK2 receptors or TRPV1 channel, abate the major signs of the
inflammatory allergic response in mouse airways. In addition, and
more importantly, initial [23,56] and more recent [24] studies
show the failure of either selective NK1 receptor antagonists or
dual NK1/NK2 tachykinin receptor antagonist to afford protec-
tion in asthma. If neurogenic inflammation plays a role in murine
models of asthma but no role in human asthma, this does not
exclude a TRPA1 contribution to the disease via non-neuronal
mechanisms. Thus, non-neuronal TRPA1 may be involved in the
dramatic inhibition of ovalbumin induced inflammation produced
by genetic deletion or pharmacological antagonism of the channel
[22].
It should be underlined that in the present experiments the non-
neurogenic proinflammatory action of CSE or acrolein, both in
vitro in human cells and in vivo in mice, was not entirely dependent
on TRPA1 activation. This is particularly evident in the study of
KC release by CS in TRPA1-deficient mice and in the study of IL-
8 release by acrolein in bronchial smooth muscle cells. Thus,
mechanisms additional to TRPA1 most likely contribute to the
early and delayed events associated with the origin and
progression of inflammatory airway diseases. In addition, we
acknowledge that our analysis is partial, as we have in depth
studied only the IL-8/KC release, whereas other mediators, whose
Figure 4. TRPA1 mediates IL-8 release by acrolein from human airway/lung cells in primary culture. Overnight exposure to acrolein
(ACR) induces IL-8 release from small airway epithelial cells (SAEC) (A), normal human lung fibroblasts (NHLF) (B) and human bronchial smooth
muscle cells (HBSMC) (C) in a concentration–dependent manner. IL-8 release evoked by ACR is reduced by HC-030031 (HC, 30 mM) and AP18 (10 mM).
Each column represents mean 6 SEM of at least 3 independent experiments. 1P,0.05 vs. Basal group or Veh/Veh-ACR; *P,0.05 vs. Veh/ACR.
doi:10.1371/journal.pone.0042454.g004
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release was found to be reduced in TRPA1-deficient mice, were
not further investigated. Nevertheless, if this paradigm, based on
IL-8/KC, were applicable to other inflammatory mediators and
human asthma and COPD, TRPA1 could represent a highly
needed novel target, and TRPA1 antagonists might be regarded as
novel medicines, for the treatment of inflammatory respiratory
diseases by targeting not only the channel expressed in sensory
nerve terminals to reduce cough [48,57], but, more importantly, in
resident non-neuronal cells to limit inflammation in airway and
lung tissue.
Materials and Methods
Ethics Statement
Mice were housed in a temperature- and humidity-controlled
vivarium (12 hours dark/light cycle, free access to food and
water). Animal experiments were carried out in conformity to the
ECC guidelines for animal care procedures and the Italian and
Swedish legislation (DL 116/92 and SFS1998:56, respectively)
application of the European Communities Council Directive 86/
609/EEC. Studies were conducted under the University of
Florence researchpermit number 143/2008-B and Chiesi Farm-
aceutici research permit number 156/2009, approved by the
Italian National Committee for animal research and under
AstraZeneca R&D research permit reference number 31-11684/
08 (Ethical approval number M284/08) and approved by the
Ethical Committee for Animal Experiments (Jordbruksverket).
Ethical approval for the experiments performed on human tissue
was obtained from the Ethics Committee of the University
Hospital of the Florence University (Comitato Etico Locale
(CEL), Azienda Ospedaliero Universitaria Careggi; approval
number 24/09).
Figure 5. TRPA1 mediates IL-8 release by cigarette smoke extract from human airway/lung cells in primary culture. IL-8 release
induced by overnight exposure to increasing concentrations (expressed as optical density, OD) of cigarette smoke extract (CSE) in small airway
epithelial cells (SAEC) (A), normal human lung fibroblasts (NHLF) (B) and human bronchial smooth muscle cells (HBSMC) (C). IL-8 release evoked by
CSE is reduced by HC-030031 (HC, 30 mM) and AP18 (10 mM). Each column represents mean 6 SEM of at least 3 independent experiments. 1P,0.05
vs. Basal group or Veh/Veh-CSE; *P,0.05 vs. Veh/CSE.
doi:10.1371/journal.pone.0042454.g005
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Animals
Male C57BL/6 mice (25 g) (Harlan Laboratories), wild-type
(Trpa1+/+) or TRPA1-deficient mice (Trpa12/2) generated by
heterozygous mice on a C57BL/6 background kindly donated by
Prof. D. Julius (UCSF, CA) [14], were used. Some in vivo
experiments, as indicated B6129P in the results section, were
performed in mice derived from crosses of Trpa12/2 (B6;129P-
Trpa1tm1Kykw/J) and wild-type (B6129PF2/J) mice (Jackson
Laboratories), generated by heterozygous mice on a C57BL/6
background. All experiments with TRPA1-deficient and wild-type
littermates were performed blinded to the genotype. Animals were
sacrificed with a high dose of i.p. sodium pentobarbital (200 mg/
kg).
Cell Culture
Human small airway epithelial cells (SAEC), normal human
lung fibroblasts (NHLF) and human bronchial smooth muscle cells
(HBSMC) were purchased from Lonza. Human alveolar type II
epithelium-like adherent cell line (A549) and human lung
embryonic fibroblast (IMR90) were purchased from American
Type Culture Collection (Manassas, VA). SAEC and NHLF were
cultured respectively in SAGM and FBM medium (Lonza)
according to the manufacturer’s instructions. IMR90 and
HBSMC were cultured in DMEM supplemented with 10%
FBS, 2 mM glutamine, 100 U penicillin and 100 mg/ml strepto-
mycin (Sigma-Aldrich), and A549 were cultured in RPMI
supplemented with 10% FBS, 2 mM glutamine, 100 U penicillin,
100 mg/ml streptomycin and 1 mM HEPES (Sigma-Aldrich). All
cells were cultured in an atmosphere of 95% air and 5% CO2 at
37uC.
Production of cigarette smoke extract (CSE)
CSE was generated as previously reported [41]. Briefly, aqueous
CSE was obtained from the combustion of four cigarettes
(Marlboro Red, 12 mg of tar, 0.9 mg of nicotine each) bubbled
through 50 ml of buffer and subsequently filtered through a 0.2-
mm pore filter (Millipore). To ensure reproducibility among
different CSE batches, the absorbance (optical density; OD)
measured at 320 nm was used as a measure of the ‘‘strength’’ of
the extract. Dilutions were made with buffer to obtain the desired
absorbance. The CSE was freshly prepared on the day of the
experiment and used immediately after preparation.
Real-Time PCR
For Real-Time PCR studies, cells were seeded in complete
culture medium in 96-well and grown to ,80–90% confluence.
Adherent cells were rinsed with cold PBS and cell lysates, and
reverse transcriptase reactions were performed using the TaqMan
Gene Expression Cells-to-Ct Kit (Applied Biosystems). Briefly,
cells were lysed in Cell Lysis solution containing DNAse I for
5 min, followed by two-min incubation with the stop solution. Cell
lysates were immediately used for RT reactions; 50 ml reverse
transcription reactions were performed using 10 ml of each cell
lysate, according to the manufacturer’s instructions. Two sets of
primers-probes were designed using the Primer Express Software
version 3.0 (Applied Biosystems). The chosen reporter fluoro-
phores for TaqMan MGB probes were VIC for the endogenous
reference b-actin gene (ACTB) and 6-carboxyfluorescein (FAM)
for TRPA1 gene. The two sets of primers-probes were as follows:
set 1, ACTB-FW (forward) 59- GGCGGCACCACCATGTAC-
39, ACTB-RE (reverse) 59-CAGGGCAGTGATCTCCTTCTG-
39, ACTB probe 59-VIC-TGGCATTGCCGACAGG-39; and set
2, TRPA1-FW (forward) 59- GGCAGTTGGCGACATTGC-39,
TRPA1-RE (reverse) 59-CTGATCCACTTTGCGTAGAAACC-
39 and TRPA1 probe 59-FAM-CATCATTGAAGAGGA-
TAGCTA-39. The chosen primers and probes were subjected to
Basic Local Alignment Search Tool (BLAST) database searches to
find any sequence similarities. Real-Time quantitative PCR was
performed using StepOnePlusTM Real-Time PCR System (Ap-
plied Biosystems, Foster City, CA). All samples were run in
triplicate in a final volume of 25 ml containing 12.5 ml of 26
TaqMan Gene Expression PCR Master Mix, 300 nM of each
primer, 250 nM of each probe and 4 ml of RT reaction, according
to the manufacturer’s instructions (Applied Biosystems). Amplifi-
cation conditions were: 50uC for 2 min and 95uC for 10 min,
followed by 40 cycles of 95uC for 30 s and 60uC for 1 min.
Relative expression of TRPA1 mRNA was calculated using the
2-D(DCT) comparative method, with each gene normalized against
the internal endogenous reference b-actin gene for the same
sample.
Immunohistochemistry
Sections of 4 mm thickness were cut from formalin-fixed,
paraffin-embedded samples of human normal lung tissue obtained
from patients who were undergoing surgery for lung cancer. All
specimens seemed macroscopically normal, without signs of tumor
or inflammation. Sections were processed with rabbit polyclonal
TRPA1 antibody (1:250 overnight 4uC, Novus Biologicals) [29].
Negative control has been obtained by substituting the primary
antibody with normal serum. In another set of experiments,
Trpa1+/+ or Trpa12/2 mice were perfused via the right ventricle
with 20 ml of PBS, and lung and trigeminal ganglia were removed
in 10% formalin, and after embedding in paraffin, 4 mm sections
were immunohistochemically stained with rabbit polyclonal
TRPA1 antibody (1:500, 2 hours 37uC, AVIVA System Biology)
which recognizes the middle region of the protein, (residues 540–
589) or with rabbit polyclonal TRPV1 antibody (1:200, overnight
4uC, Alomone Labs). Specificity of staining was determined by
preadsorption with immunizing peptide (1:250, overnight 4uC,
AVIVA Biosystem). Serial sections of mouse and human lung
tissues were processed with anti-cytokeratin (1:250, overnight
22uC, Abcam), anti-a-smooth muscle actin (1:200, overnight
22uC, Abcam) and anti-TRPV1 (1:200, overnight 4uC, Alomone
Labs) antibodies. Immunostaining was performed according to
standard procedures. Briefly, the slides were dewaxed in Bio-Clear
(Bio-Optica) and hydrated with grade ethanol concentrations until
distilled water. Antigen retrieval was routinely performed by
immersing the slides in thermostat bath containing 10 mM citrate
buffer (pH 6.0) for 15 min at 97uC followed by cooling for 20 min
at room temperature. Endogenous peroxidase activity was blocked
by treating the sections with 3% hydrogen peroxide in distilled
water for 10 min. After blocking with normal horse serum
(UltraVision), sections were incubated with the respective
antibodies. Bound antibodies were visualized using aminoethyl-
carbazol and 3.39diaminobenzidine (LabVision) as chromogens.
Nuclei were counterstained with Mayer’s haematoxylin. Negative
controls were performed by substituting the primary antibody with
a nonimmune serum. Details for immunofluorescence method are
available online as (Text S1).
Calcium Imaging
For calcium fluorescence measurements, cells were incubated
with 5 mM Fura-2AM ester (Alexis Biochemicals) for 40 minutes at
37uC. Intracellular calcium levels were measured and recorded
with a dynamic image analysis system (Laboratory Automation
2.0; RC Software). Fluorescence was measured during excitation
at 340 and 380 nm, and after correction for the individual
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background fluorescence signals, the ratio of the fluorescence at
both excitation wavelengths (Ratio340/380) was monitored. Exper-
iments were performed using buffer solution containing (in mM):
150 NaCl, 6 KCl, 1 MgCl2, 1.5 CaCl2, 10 glucose, 10 HEPES at
pH 7.4. Cells were stimulated with cinnamaldehyde (0.1–
3000 mM), acrolein (0.1–3000 mM), CSE (0.001–0.5 OD), capsa-
icin (1 mM) and the activating peptide (SLIGKV-NH2) of the
human PAR-2 receptor (hPAR-2 AP; 100 mM), or their respective
vehicles (0.3% DMSO,aqueous buffer or 1% ethanol). HC-030031
and AP18 vehicles (used in all the in vitro experiments) were 3%
DMSO and 1% DMSO, respectively. Results are expressed as the
increase of Ratio340/380 over the baseline normalized to the
maximum effect induced by ionomycin (5 mM) added at the end of
the experiment.
Desensitization to resiniferatoxin
To defunctionalize/desensitize TRPV1 expressing primary
sensory neurons, resiniferatoxin (RTX) was administered to
C57BL/6 mice, as previously described [39,40]. Briefly, mice
were treated subcutaneously (s.c.) with a single injection of RTX
(50 mg/kg) or its vehicle (10% ethanol and 10% tween 80 in
isotonic saline) into the scruff of the neck under a light ether
anesthesia to avoid unnecessary pain. Experiments were carried
out 7 days after RTX treatment when responses to both TRPV1
and TRPA1 agonists in the treated mice were abolished [39,40].
Plasma Protein Extravasation
Anesthetized (sodium pentobarbital, 50 mg/kg i.p.) C57BL/6
mice received Evans blue dye (30 mg/kg i.v.), 1 min before
intratracheal (i.t) instillation (30 ml) of acrolein (5 mM), capsaicin
(100 mM), SP (25 nM), CSE (1 OD) or their vehicles (isotonic
saline, 1% ethanol in isotonic saline and isotonic saline). Drugs
were given to mice through the intratracheal route after exposing
the trachea and by inserting a 30-gauge needle just below the
inferior laryngeal rim. The tachykinin NK1 receptor antagonist,
L-733,060 (2 mmol/kg i.v.; Tocris) or its vehicle were administered
15 min before the stimulus. The TRPV1 selective antagonist,
capsazepine, (30 mg/kg i.p.) or its vehicle (2.5% DMSO in
isotonic saline) and intragastric (i.g.) TRPA1 selective antagonist,
HC-030031 (300 mg/kg i.g.) or its vehicle were administered 30
and 60 min before the stimulus, respectively. In another set of
experiments ACR (5 mM, i.t.), or its vehicle, has been adminis-
tered in C57BL/6 mice desensitized to RTX (50 mg/kg; s.c.).
Animals were euthanized 15 min after treatment and transcar-
dially perfused with 0.9% isotonic saline solution. The extrava-
sated dye was extracted from mouse trachea and bronchi by
overnight incubation in formamide and assayed by spectropho-
tometry at 620 nm, as reported previously [20].
Bronchoalveolar Lavage
Trpa1+/+ or Trpa12/2 B6129P mice (5 per group) were exposed
acutely to the cigarette smoke (CS) produced with commercial
cigarettes (Marlboro Red, 12 mg of tar, 0.9 mg of nicotine each),
by using a ‘‘nose-only’’ exposure unit. The smoke produced by
cigarette burning was introduced into the exposure chamber (inner
volume= 11.61 l) with the airflow generated by a mechanical
ventilator (7025 Rodent Ventilator, Ugo Basile) at a rate of
250 ml/min [58]. A second mechanical ventilator was used to
provide room air for dilution (1:8) of the smoke stream. Mice were
exposed to the smoke of 5 cigarettes per exposure period, twice
daily, for 3 consecutive days, and sacrificed 24 hours later.
Genotype-, age-, strain- and sex-matched control animals were
exposed to air only in the same manner for the same duration of
time. Anesthetized C57BL/6, and Trpa1+/+ or Trpa12/2 (C57BL/
6) mice were intratracheally administered with (30 ml) acrolein
(5 mM), capsaicin (100 mM), SP (25 nM) and CSE (1 OD) or their
vehicles (isotonic saline, 1% ethanol in isotonic saline and isotonic
saline) and sacrificed 24 hours later. The NK1 receptor antago-
nist, L-733,060 (2 mmol/kg i.v.; Tocris) or its vehicle (isotonic
saline) were administered 15 min before the stimulus, and i.g. HC-
030031 (300 mg/kg) or its vehicle (0.5% CMC in isotonic saline
0.9%) were administered 1 hour before the stimulus. In another
set of experiments ACR (5 mM, i.t.), or its vehicle, has been
administered in C57BL/6 mice desensitized to RTX (50 mg/kg;
s.c.). Animals were sacrificed 24 hours after the last exposure/
treatment with an overdose of anesthetic followed by exsanguina-
tion, and the lungs were lavaged using a cannula inserted into the
trachea and instilling 1 ml of Hank’s Buffer added with HEPES
10 mM and EDTA 10 mM three times. Routine recovery of BAL
did not significantly differ between animals with ,80% of instilled
volume recovered. BAL were centrifuged at 2006 g at 4uC for
10 min, and the cell-free supernatants were stored at 280uC for
cytokine determination. Frozen cell-free BAL was analyzed for
keratinocyte chemoattractant (CXCL-1/KC, the murine analogue
of IL-8) release by using a commercial ELISA-assay (Invitrogen).
IL-8 release and ELISA assay
For IL-8 ELISA assays, HBSMC, SAEC, and NHLF were
seeded in complete culture medium in 48-well plates, grown to
,80–90% confluence, and incubated overnight in serum-free
medium before treatments. All the treatments were performed in
serum free medium. Cells were pretreated with the selective
TRPA1 antagonists, HC-030031 and AP18, or their vehicles, for
30–60 min before treatment with freshly prepared acrolein, CSE,
TNF-a and IL-1b for 18 hours at 37uC with 5% CO2.
Subsequently, supernatants were collected and stored at 280uC
for ELISA assay. Human IL-8 was measured using a paired
antibody quantitative ELISA kit (Invitrogen) (detection limit:
5 pg/ml). The assays were performed according to the manufac-
turer’s instructions. Vitality assay method (MTT reduction assay)
is available online as (Text S1).
Statistical Analysis
Analyses were performed using GraphPad Prism 5 statistical
software. All data were expressed as mean 6 SEM or Confidence
Interval (CI). Agonist potency was expressed as EC50, that is, the
molar concentration of agonist producing 50% of the measured
effect. Statistical significance was determined by using one- or two-
way ANOVA, followed by Bonferroni’s post hoc analysis for
comparison of multiple groups and the unpaired 2-tailed Student’s
t-test between 2 groups. P,0.05 was considered significant.
Supporting Information
Figure S1 Immunoistochemical and immunofluores-
cent staining of TRPA1 protein. (A) Immunoistochemical
and immunofluorescent staining for TRPA1 protein in sections of
trigeminal ganglia obtained from Trpa1+/+ and Trpa12/2 mice.
Double labeling fluorescence with cytokeratin or a-smooth muscle
actin (a-SMA) (red) and TRPA1 (green) antibodies in human (B)
and Trpa1+/+ mice (C) airways/lung tissues. Scale bar 100 mm for
immunohistochemistry and 50 mm for immunofluorescence.
(TIF)
Figure S2 Immunoistochemistry of TRPV1 in mouse
and human airways and in trigeminal ganglia obtained
from mice. TRPV1 staining is absent in epithelial or smooth
muscle cell layers in mouse and human airways/lung tissues (A
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and B). (C) Immunoistochemical staining for TRPV1 protein in
sections of mouse trigeminal ganglia. Scale bar 100 mm.
(TIF)
Figure S3 Functional TRPA1 receptors are expressed in
human airway/lung cells. Typical traces and concentration-
dependent intracellular calcium response induced by selective
TRPA1 agonists, cinnamaldehyde (CNM, typical traces and black
circles) and acrolein (ACR, grey circles), and by cigarette smoke
extract (CSE, black triangles) in human type II alveolar epithelial
cell line (A549) (A) and human fetal lung fibroblasts (IMR90) (B).
The calcium response evoked by CNM, ACR or CSE both in
A549 (A) and IMR90 (B) is abolished by selective TRPA1
antagonists, HC-030031 (HC, 10 mM) or AP18 (10 mM). Calcium
response elicited by stimulation with PAR-2 receptor activating
peptide (SLIGKV-NH2) (PAR-2 AP, 100 mM) is not affected by
TRPA1 antagonists, indicating selectivity. Veh is a combination of
vehicles of HC and AP18. Values represent mean 6 SEM of
n.25 cells. 1P,0.05 vs. Veh.
(TIF)
Figure S4 Inflammatory mediators analysis of BAL
fluid taken from Trpa1+/+ and Trpa12/2 mice exposed
to cigarette smoke (CS) for 5 consecutive days. CS
exposure increases significantly KC, IL-5, MMP9, TIMP-1, IL-
1b, IL-2, MCP-1, IL-13 levels in Trpa1+/+ mice BAL. Increases in
KC, IL-5, MMP-9 and TIMP-1 evoked by CS exposure are
significantly reduced in BAL of Trpa12/2 mice. Each column
represents mean 6 SEM of at least 5 mice per group. *P,0.05 vs.
air-exposed Trpa1+/+ mice. #P,0.05 vs. Trpa1+/+ CS group.
(TIF)
Figure S5 IL-8 release from cultured cells of the human
respiratory tract by IL-1b or TNF-a is not mediated by
TRPA1. IL-8 release induced by overnight exposure to IL-1b or
to TNF-a in small airway epithelial cells (SAEC) (A, D), normal
human lung fibroblasts (NHLF) (B, E) and human bronchial
smooth muscle cells (HBSMC) (C, F) is not affected by TRPA1
antagonists, HC-030031 (HC, 30 mM) and AP18 (10 mM). Each
column represents the mean 6 SEM of at least 3 independent
experiments. 1P,0.05 vs. Basal group or Veh/Veh-ACR;
*P,0.05 vs. Veh/ACR. Effect of cigarette smoke extract (CSE)
exposure on cell viability evaluated by using the [3-(4,5-
dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide] (MTT)
test in small airway epithelial cells (SAEC) (G), normal human lung
fibroblasts (NHLF) (H) and human bronchial smooth muscle cells
(HBSMC) (I). Each column represents mean 6 SEM of at least 3
independent experiments 1P,0.05 vs. Basal group.
(TIF)
Text S1 Methods.
(DOCX)
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